Medtech Advised To Prepare For Significant Updates In China’s Classification Catalogue
Revisions to China’s classification catalogue have now been finalized and they will have considerable impact on device registration, according to law firm Ropes & Gray.
You may also be interested in...
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.